Research programme: gp96-based vaccines - University of Miami/Zolovax

Drug Profile

Research programme: gp96-based vaccines - University of Miami/Zolovax

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Miami
  • Developer University of Miami; Zolovax
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Dengue; HIV infections; West Nile virus infections; Yellow fever; Zika virus infection

Most Recent Events

  • 14 Nov 2016 Zolovax has patent protection for gp96 vaccines
  • 14 Nov 2016 Early research in Dengue in USA before November 2016 (unspecified route)
  • 25 Oct 2016 Early research in HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top